Souhaitez-vous accéder aux communiqués récents ?

Novel treatment for moderate to severe acne Oslo, Norway, October 30, 2013: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and...

Oslo, Norway, 23 October 2013: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for the third...

Photocure will present its third quarter 2013 report on Wednesday 23 October 2013 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives from the company...

The annual report for Photocure ASA (the "Company") for 2012 has previously been made available at the Company's web page: http://www.photocure.com/Investor-relations/, and is now also published on...

  This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. ...

Oslo, Norway, 22 August 2013: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, today announces its results for the...

Photocure will present its second quarter and first half 2013 report on Thursday 22 August 2013 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives...

Oslo, Norway, August 8, 2013: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announced today that Ingrid Wiik, a member...

Oslo, 23. mai 2013 Aksjene i Photocure ASA noteres eksklusiv utbytte NOK 2,00 fra og med i dag, 23.mai 2013. For ytterligere informasjon, vennligst kontakt: PhotocureFinansdirektør Erik DahlTel:...

Oslo, Norway, 23 May, 2013. The shares in Photocure ASA will be traded exclusive dividend NOK 2.00 as from today, 23 May 2013. For further information, please contact: PhotocureCFO Erik DahlTel:...